This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Stubbs, M. C. Articles by Armstrong, S. A. Search for Related Content PubMed PubMed Citation Articles by Stubbs, M. C. Articles by Armstrong, S. A.

Therapeutic Implications of Leukemia Stem Cell Development

Authors' Affiliation: Division of Hematology/Oncology, Children's Hospital Boston, Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts

Requests for reprints: Scott A. Armstrong, Karp Family Research Laboratories, Children's Hospital Boston, 1 Blackfan Circle, Boston, MA 02215. Phone: 617-919-2508; Fax: 617-730-0934; E-mail: Scott.Armstrong{at}childrens.harvard.edu.

Abstract

Acute myelogenous leukemias, and perhaps many other cancers, are maintained by a population of cancer stem cells that can regenerate themselves as well as give rise to more differentiated and less proliferative cells that constitute the bulk of the disease. Recent discoveries have shed light on both the nature of leukemia stem cells (LSC) and their cells of origin. Here, we review which hematopoietic cells could give rise to LSC, and the phenotype of fully developed LSC. The perturbed developmental pathways and cellular context of LSC development have implications for the development of new therapeutic approaches.